title: Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer.
authors.affiliation: Department of Medical Oncology, University of Glasgow, UK.
authors.forename: M J
authors.initials: MJ
authors.lastname: Harding
authors.forename: B M
authors.initials: BM
authors.lastname: Cantwell
authors.forename: R A
authors.initials: RA
authors.lastname: Milstead
authors.forename: A L
authors.initials: AL
authors.lastname: Harris
authors.forename: S B
authors.initials: SB
authors.lastname: Kaye
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005492:Folic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; C031662:CB 3717; D005492:Folic Acid